Alnylam Pharmaceuticals Inc. (ALNY): Price and Financial Metrics

Alnylam Pharmaceuticals Inc. (ALNY): $149.45

4.94 (-3.20%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add ALNY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#31 of 365

in industry

ALNY Price/Volume Stats

Current price $149.45 52-week high $218.88
Prev. close $154.39 52-week low $143.52
Day low $149.32 Volume 666,500
Day high $154.50 Avg. volume 869,823
50-day MA $161.05 Dividend yield N/A
200-day MA $177.42 Market Cap 18.82B

ALNY Stock Price Chart Interactive Chart >

ALNY POWR Grades

  • ALNY scores best on the Quality dimension, with a Quality rank ahead of 90.03% of US stocks.
  • The strongest trend for ALNY is in Stability, which has been heading down over the past 26 weeks.
  • ALNY's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).

ALNY Stock Summary

  • ALNYLAM PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 1.46% of US listed stocks.
  • Price to trailing twelve month operating cash flow for ALNY is currently 12,125.68, higher than 99.96% of US stocks with positive operating cash flow.
  • ALNY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.84% of US stocks.
  • Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are ATRC, BRZE, QNST, ABCL, and ACVA.
  • ALNY's SEC filings can be seen here. And to visit ALNYLAM PHARMACEUTICALS INC's official web site, go to www.alnylam.com.

ALNY Valuation Summary

  • ALNY's EV/EBIT ratio is -63.4; this is 534.25% lower than that of the median Healthcare stock.
  • Over the past 238 months, ALNY's price/sales ratio has gone down 421.6.

Below are key valuation metrics over time for ALNY.

Stock Date P/S P/B P/E EV/EBIT
ALNY 2023-12-29 13.9 -144.8 -47.1 -63.4
ALNY 2023-12-28 14.2 -148.1 -48.2 -64.8
ALNY 2023-12-27 14.3 -148.7 -48.4 -65.1
ALNY 2023-12-26 13.9 -144.7 -47.1 -63.4
ALNY 2023-12-22 13.9 -144.5 -47.0 -63.3
ALNY 2023-12-21 13.2 -137.0 -44.6 -60.1

ALNY Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -11.3%.
  • The 3 year cash and equivalents growth rate now stands at -26.33%.
  • Its year over year price growth rate is now at 2.48%.
ALNY's revenue has moved up $288,104,000 over the prior 15 months.

The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,037.418 -541.274 -1,131.156
2022-09-30 960.918 -559.437 -1,182.123
2022-06-30 884.245 -578.189 -980.717
2022-03-31 879.98 -577.226 -892.874
2021-12-31 844.287 -641.693 -852.824
2021-09-30 749.314 -614.696 -837.904

ALNY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
  • ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
  • QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.

The table below shows ALNY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.220 0.833 -0.249
2021-06-30 0.204 0.833 -0.267
2021-03-31 0.171 0.832 -0.272
2020-12-31 0.159 0.842 -0.308
2020-09-30 0.141 0.832 -0.372
2020-06-30 0.130 0.853 -0.416

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $184.16 Average Broker Recommendation 1.64 (Moderate Buy)

Alnylam Pharmaceuticals Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. (Source:Wikipedia)


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug

The clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam.

Yahoo | December 22, 2023

13 Most Promising Healthcare Stocks According to Analysts

In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […]

Yahoo | December 19, 2023

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

CAMBRIDGE, Mass., December 13, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2024, including continued commercial execution of four RNAi therapeutic products and the advancement of early-, mid-, and late-stage investigational programs.

Yahoo | December 13, 2023

Alnylam to Webcast Virtual R&D Day

CAMBRIDGE, Mass., December 06, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.

Yahoo | December 6, 2023

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

CAMBRIDGE, Mass., November 30, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the "Largest Employer" category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees).

Yahoo | November 30, 2023

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -3.72%
3-mo -21.92%
6-mo -15.61%
1-year -23.41%
3-year 10.60%
5-year 59.93%
YTD -21.92%
2023 -19.46%
2022 40.14%
2021 30.48%
2020 12.85%
2019 57.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!